ASAS-EULAR Recommendations and Bimekizumab’s Novel Action in SpA

Get updated on the new ASAS-EULAR recommendations for the full spectrum of Axial SpA and on the new mode of action, bimekizumab, an IL-17A and F inhibitor, by Sofia Ramiro, rheumatologist from the Netherlands from Leiden University Medical Center.